Physician profile
Ritu Ajit Kumar
NPI 1891873238
$1,592.57
in general payments reported to CMS, 2019-2025
15 companies · $14.47 in 2025
The $14.47 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $216 · 2021: $350 · 2022: $144 · 2023: $291 · 2024: $61.37 · 2025: $14.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.34 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $190.53 | 2019-2023 | Dovato |
| Janssen Biotech, INC. | $186.90 | 2019-2023 | Symtuza |
| Melinta Therapeutics, LLC | $177.68 | 2019-2024 | Orbactiv, Kimyrsa, Vabomere |
| Merck Sharp & Dohme LLC | $162.22 | 2019-2023 | Zerbaxa, Dificid |
| Abbvie INC. | $150.81 | 2021-2023 | |
| Insmed, INC. | $148.77 | 2019-2023 | Arikayce |
| Allergan, INC. | $141.05 | 2019-2020 | |
| Shionogi INC | $121.66 | 2022-2025 | Fetroja |
| Gilead Sciences, INC. | $98.51 | 2019-2023 | Veklury |
| Theratechnologies INC. | $62.40 | 2019 | |
| La Jolla Pharmaceutical Company | $45.77 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $41.08 | 2020-2021 | |
| Angiodynamics, INC. | $26.40 | 2024 | Angiovac |
| Alexion Pharmaceuticals, INC. | $24.02 | 2021 | |
| Emd Serono, INC. | $14.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.